iPharmaCenter
Putting patients at center
Home
COVID-19
News
Conferences
Healthcare Policies & Systems
Regional News
North America
Europe
APAC
Patient info
More
Use tab to navigate through the menu items.
USA
BMS' Breyanzi was approved for relapsed or refractory LBCL | News | FDA | iPharmacenter
Lilly's and Incyte's Olumiant approved for adults with severe alopecia areata
FDA approved two Opdivo based regimens as a 1L treatment for ESCC | FDA News | iPharmaCenter
FDA approved Kymriah for follicular lymphoma | Novartis | News | Cancer | | Updates | iPharmaCenter
CMS News | HHS | USA | Medicare, and Medicaid | Health insurance | Healthcare News
2022 FDA Drug Approvals
COVID19 drug updates | FDA EMA approved COVID19 drugs
FDA gave the nod to Pfizer's Paxlovid | Pfizer to supply 2.5 million doses of Paxlovid to the UK
~$10 bn acquisition paying off for Novartis as FDA approved Novartis' Leqvio
Myasthenia Gravis News | FDA and EMA approvals |
American College of Rheumatology (ACR) Convergence all-virtual annual meeting Updates
Despite facing criticism on handling the COVID19 situation, Tedros to continue as WHO chief
FDA approved Novartis Scembli for chronic myeloid leukemia
Biogen's Aduhelm received FDA approval for Alzheimer's disease; ICER criticized approval
CMS News | US Healthcare News | Medicare and Medicaid News |
GSK’s Jemperli received approval in Europe and the US for endometrial cancer
Gilead’s Trodelvy approved for triple-negative breast cancer in US
BMS’ and bluebird bio’s Abecma approved by US FDA; first CAR T cell therapy for multiple myeloma
FDA to review the accelerated approvals of Keytruda, Opdivo, and Tecentriq
Novartis’ blockbuster Entresto received the US FDA approval for a broader target population
US FDA approved BMS gene therapy Breyanzi
Merck and Bayer announced the US FDA approval for Verquvo
Expected best selling pharmaceutical products (drugs) in 2021
Novartis and BeiGene collaboration strengthens the Swiss drugmaker's oncology portfolio
Biogen initiated Phase 4 trial to determine the efficacy of Spinraza in Zolgensma treated patients
REGENERON'S INMAZEB FIRST PRODUCT TO RECEIVE FDA APPROVAL FOR TREATING EBOLA VIRUS
CMS News
FDA approved GSK’s Nucala for Hypereosinophilic Syndrome
J&J has initiated the Phase 3 clinical trial of the COVID-19 vaccine
Pfizer received the approval of Xalkori for ALK-positive anaplastic large cell lymphoma
To strengthen the oncology portfolio, Merck collaborated with Seattle Genetics, and Gilead acquired
FDA approved Trelegy Ellipta for asthma, GSK’s triple therapy is now available for asthma and COPD
Oxford vaccine trials were paused because of safety concerns; AZ said it’s ‘routine’
FDA approved Roche’s Gavreto for RET fusion-positive NSCLC
FDA extended emergency use authorization of Veklury to all hospitalized patients
FDA has provided emergency use authorization for Abbott’s easy-to-use COVID-19 antigen test
FDA issued Emergency Use Authorization of Convalescent Plasma for COVID-19 treatment
Johnson and Johnson acquired Momenta Pharmaceuticals, aims to strength immunology profile
Amgen’s Kyprolis and Janssen’s Darzalex combination approved by the US FDA for multiple myeloma
Novartis Kesimpta approved for relapsing multiple sclerosis in the US
FDA says no to Gilead’s most anticipated product filgotinib
Genentech’s Enspryng approved for Neuromyelitis Optica Spectrum Disorder in the US
US FDA approved another drug for rare Duchenne Muscular Dystrophy
Gilead submitted NDA for Veklury to treat COVID-19 in the US
FDA approved Genentech’s Evrysdi for Spinal Muscular Atrophy
NOVARTIS COSENTYX APPROVED IN EUROPE FOR PAEDIATRIC PSORIASIS
GSK’s first anti-BCMA therapy Blenrep was approved in the US
Gilead’s CAR-T cell therapy approved for Relapsed or Refractory Mantle Cell Lymphoma
The US FDA approved Janssen’s psoriasis blockbuster for Psoriatic Arthritis
UNITED STATES HEALTHCARE SYSTEM
EUROPE
HAS ASSESSMENT OUTCOMES | FRANCE PHARMA NEWS
NICE ASSESSMENT OUTCOMES
Roche’s Polivy was approved as first-line therapy for patients with DLBCL.
Drug approvals in Europe in 2022 | EMA drug approvals in 2022 | European Commission News
2022 | CHMP Positive Opinions | EMA Drug Approvals | European Commission | Pharma | News
COVID19 drug updates | FDA EMA approved COVID19 drugs
JAPAN
Despite facing criticism on handling the COVID19 situation, Tedros to continue as WHO chief
Levima received orphan designation from MHLW |Japan drug approvals | Japan Healthcare System
Expected best selling pharmaceutical products (drugs) in 2021
Lynparza was approved for three more indications in Japan
Merck’s Keytruda received one more indication and dosage form approval in Japan
Gilead announced the positive Phase 3 trial of remdesivir in COVID-19 patients
AUSTRALIA